- Home
- CHW vs LXRX Comparison
CHW vs LXRX Comparison
Compare CHW & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CHW | LXRX |
|---|---|---|
| Founded | 2007 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 462.4M | 447.0M |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | CHW | LXRX |
|---|---|---|
| Price | $7.61 | $1.17 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $3.23 |
| AVG Volume (30 Days) | 195.2K | ★ 1.7M |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 9.27% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $70,864,000.00 |
| Revenue This Year | N/A | $56.61 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 1255.21 |
| 52 Week Low | $5.07 | $0.28 |
| 52 Week High | $6.54 | $1.66 |
Technical Indicators
Market Signals| Indicator | CHW | LXRX |
|---|---|---|
| Relative Strength Index (RSI) | 64.05 | 46.50 |
| Support Level | $7.40 | $1.12 |
| Resistance Level | $7.48 | $1.23 |
| Average True Range (ATR) | 0.08 | 0.07 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 95.00 | 46.34 |
Price Performance
Historical ComparisonAbout CHW Calamos Global Dynamic Income Fund
Calamos Global Dynamic Income Fund operates as a closed-end management investment company. The company's investment objective is to generate a high level of current income with the objective of capital appreciation. It dynamically allocates its investment among equities, convertible bonds, fixed-income securities and alternative investments.
About LXRX Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.